98%
921
2 minutes
20
Sequential multiple assignment randomized trials (SMARTs) are the gold standard for estimating optimal dynamic treatment regimes (DTRs), but are costly and require a large sample size. We introduce the multi-stage augmented Q-learning estimator (MAQE) to improve efficiency of estimation of optimal DTRs by augmenting SMART data with observational data. Our motivating example comes from the Back Pain Consortium, where one of the overarching aims is to learn how to tailor treatments for chronic low back pain to individual patient phenotypes, knowledge which is lacking clinically. The Consortium-wide collaborative SMART and observational studies within the Consortium collect data on the same participant phenotypes, treatments, and outcomes at multiple time points, which can easily be integrated. Previously published single-stage augmentation methods for integration of trial and observational study (OS) data were adapted to estimate optimal DTRs from SMARTs using Q-learning. Simulation studies show the MAQE, which integrates phenotype, treatment, and outcome information from multiple studies over multiple time points, more accurately estimates the optimal DTR, and has a higher average value than a comparable Q-learning estimator without augmentation. We demonstrate this improvement is robust to a wide range of trial and OS sample sizes, addition of noise variables, and effect sizes.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11130757 | PMC |
http://dx.doi.org/10.1093/biomtc/ujae046 | DOI Listing |
Ann Intern Med
September 2025
Johns Hopkins University School of Medicine, Baltimore, Maryland (M.S., J.J., K.A.G., M.S., A.T.F.).
Background: With antiretroviral therapy, people with HIV can live a normal lifespan and not transmit HIV. The Ryan White HIV/AIDS Program provides care for over half of people with HIV in the United States.
Objective: To estimate how many HIV infections could result from cessation of Ryan White services or interruptions lasting 18 to 42 months.
J Med Internet Res
September 2025
School of Governance and Policy Science, The Chinese University of Hong Kong, Hong Kong, China (Hong Kong).
Background: Older adults are more vulnerable to severe consequences caused by seasonal influenza. Although seasonal influenza vaccination (SIV) is effective and free vaccines are available, the SIV uptake rate remained inadequate among people aged 65 years or older in Hong Kong, China. There was a lack of studies evaluating ChatGPT in promoting vaccination uptake among older adults.
View Article and Find Full Text PDFJMIR Aging
September 2025
Department of Geriatrics, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Background: Sarcopenia is associated with cardiovascular diseases (CVDs). However, whether changes in sarcopenia status affect CVD risk remains unclear. In addition, how indoor fuel use impacts the sarcopenia transition process is less well studied.
View Article and Find Full Text PDFNeurology
October 2025
Alzheimer's Disease and Other Cognitive Disorders Unit, Department of Neurology, Hospital Clínic de Barcelona, Fundació Recerca Clínic Barcelona-IDIBAPS, Spain.
Background And Objectives: α-Synuclein seed amplification assays (αSAAs) can improve the diagnosis of synucleinopathies and detect α-synuclein (αSyn) copathology in vivo in clinical practice. We aimed to evaluate the diagnostic performance of αSAA for detecting αSyn in CSF for diagnosing dementia with Lewy bodies (DLB) in a clinical cohort of cognitively impaired individuals. We explored how the coexistence of Alzheimer disease (AD) and αSyn pathology influences biomarker levels and clinical profiles.
View Article and Find Full Text PDFAnn Am Thorac Soc
September 2025
Erasmus MC, Rotterdam, Zuid-Holland, Netherlands.
Rationale: Modulator therapies like ivacaftor have revolutionized clinical management of cystic fibrosis (CF), showing marked short-term benefits in trials but heterogeneous findings in long-term observational studies. Since newer modulators have become the standard of care for the majority living with CF in the U.S.
View Article and Find Full Text PDF